Enigmatig Limited Announces Closing of US$15 Million Initial Public Offering, Including Exercise of Over-allotment Option

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

Compass Therapeutics (CMPX) reported positive Phase 2/3 results for tovecimig in biliary tract cancer, meeting primary and key secondary endpoints. ORR improved to 18.0% vs 5.3%, and PFS to 4.7 vs 2.6 months. Data was published in the Journal of Clinical Oncology and presented at ESMO. The safety profile was consistent with prior studies.

Celcuity reported VIKTORIA-1 subgroup data showing median PFS of 21.5 months for triplet therapy, 11.5 months for doublet, vs 9.1 months for alpelisib+fulvestrant in PIK3CA MT HR+/HER2- ABC without liver mets. TEAE discontinuations were lower for Celcuity's treatments.

Compass Therapeutics (CMPX) reported positive results from the COMPANION-002 trial of tovecimig in combination with paclitaxel for advanced biliary tract cancer. The study met primary and key secondary endpoints, showing a 56% reduction in disease progression or death risk. The drug demonstrated durable responses and improved disease control rates. The safety profile was consistent with prior studies.

Bristol Myers Squibb reported a patient death in a Phase 1 trial for its CAR-T therapy targeting multiple sclerosis. The patient had pre-existing complications and died from septic pneumonia. The company noted this may impact the therapy's safety assessment. The incident raises concerns about CAR-T therapy's safety and regulatory challenges in autoimmune treatments.

Boeing 777F production halted for nearly two months due to a dispute with supplier Vaero over wing components, costing Boeing up to $6.5M per day. The 777F has 38 unfilled orders, with a backlog of about 31 aircraft. The FAA extended production through 2030, allowing up to 35 additional 777Fs. Boeing delivered 21 777Fs in 2026, with demand continuing despite the transition to the 777-8F.